D'Angelo S, Palazzi C, Olivieri I
Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza and Matera, Italy.
Reumatismo. 2012 Jun 5;64(2):113-21. doi: 10.4081/reumatismo.2012.113.
The traditional management of psoriatic arthritis (PsA) includes NSAIDs, corticosteroids and DMARDs. Advancement in the knowledge of the immunopathogenesis of PsA has been associated with the development of biologic agents which have revolutionized the management of the disease. Among biologics drugs, there are the 4 currently available anti-TNFα blocking agents (etanercept, infliximab, adalimumab and golimumab) which are more effective than traditional DMARDs on symptoms/signs of inflammation, quality of life, function, and in inhibiting the progression of the structural joint damage. Despite of the high cost, TNF inhibitors are cost-effective on both the musculoskeletal and skin manifestations of psoriatic disease.
银屑病关节炎（PsA）的传统治疗方法包括使用非甾体抗炎药、皮质类固醇和改善病情抗风湿药（DMARDs）。随着对PsA免疫发病机制认识的不断进步，生物制剂应运而生，彻底改变了该疾病的治疗方式。在生物制剂中，目前有4种抗肿瘤坏死因子α（TNFα）阻断剂（依那西普、英夫利昔单抗、阿达木单抗和戈利木单抗），它们在改善炎症症状/体征、提高生活质量、改善功能以及抑制关节结构损伤进展方面比传统DMARDs更有效。尽管成本高昂，但TNF抑制剂对银屑病的肌肉骨骼和皮肤表现均具有成本效益。
